Key result
Minimally invasive direct coronary artery bypass grafting demonstrated a 30-day mortality rate of 1.5% and a 5-year MACCE-free survival rate of 72.8%, with 88.9% graft patency at 9.7 months.
Observational (n=66)
No
MIDCAB is a safe revascularization strategy with low postoperative morbidity and mortality, offering favorable mid-term MACCE-free survival and high graft patency.
No takes yet. Share an insight, caveat, or question.
Low morbidity and favorable mid-term survival support MIDCAB feasibility in experienced centers; leaves open randomized comparisons to sternotomy CABG.
Seo et al. (2018) conducted an observational in Coronary artery disease (n=66). Minimally invasive direct coronary artery bypass grafting (MIDCAB) was evaluated on 5-year MACCE-free survival rate. Minimally invasive direct coronary artery bypass grafting demonstrated a 30-day mortality rate of 1.5% and a 5-year MACCE-free survival rate of 72.8%, with 88.9% graft patency at 9.7 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: